facebook-page-view
Advertisement

Vyome Biosciences ropes in former Emami chief executive N Venkat as CEO, former top P&G R&D executive as senior advisor

By Lohit Jagwani

  • 10 Sep 2013

Vyome Biosciences Pvt Ltd, which is a biopharmaceutical company focused on developing dermatology and skin care products, has brought on board N Venkat as promoter, co-founder and CEO of the company.

N Venkat has more than two decades of experience in building and managing companies as a senior executive. Earlier, he served as CEO and executive director of Emami, and president of companies like CavinKare, Shantha Biotechnics and Aurobindo Pharma.

“I am excited to be leading Vyome as the company moves towards commercialising some of its path-breaking technologies in advanced hair care and Rx dermatology,” Venkat said.

Advertisement

The Delhi-based company has also appointed Dr Shekhar Mitra, former senior vice president for R&D at Procter & Gamble Worldwide, as senior advisor for innovation strategy and business development. Mitra was a member of the P&G Global Leadership Council, the apex top-management group defining P&G’s strategic priorities.

“Vyome has reached an exciting stage; we expect to have efficacy data from our first clinical trial soon. We are thrilled to welcome Venkat and Shekhar as we build a strong team,” said Dr Shiladitya Sengupta, co-founder of Vyome Biosciences.

Vyome Biosciences develops research-based pharmaceutical solutions for skin conditions such as dandruff, acne, pigmentation disorders and wound healing. The company was set up in August 2010 by three people – Dr Shiladitya Sengupta of Harvard Medical School, Dr Rajesh Gokhale of Institute of Genomics and Integrative Biology and Rajeev Mantri, an executive director at early-stage investor Navam Capital. Mantri is also the president of Vyome.

Advertisement

In November 2010, Vyome Biosciences raised $1 million from Navam, an early-stage venture capital firm focusing on investments in cleantech, advanced materials, Internet, life sciences and other emerging technologies.

The company later raised $3.35 million from Kalaari Capital, Navam Capital and Aarin Capital in 2012.

(Edited by Joby Puthuparampil Johnson)

Advertisement

Share article on

Advertisement
Advertisement